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Available online 12 April 2019Background:Dysregulation of immune checkpointmolecules leads to immune evasion inhuman tumours but has
become a viable target for tumour therapy. Here, we examined expression of Herpes virus entry mediator
(HVEM), an immune checkpoint molecule, in human glioblastoma (GBM) to assess its potential as a molecular
target for treatment.
Methods: Molecular and clinical data from publicly available genomic databases containing WHO grade II-IV
human glioma cases (n = 1866) were analyzed. Immunohistochemistry was applied to assess HVEM protein
levels in primary tumour sections. Statistical analysis was performed using Matlab and R language.
Findings: HVEM was found to be elevated in aggressive gliomas, particularly in the mesenchymal and isocitrate
dehydrogenase (IDH)wild-typemolecular subtypes of GBM.HVEMhigh tumours tended to be associatedwith am-
plification of EGFR and loss of PTEN, whileHVEMlow tumours harboredmutations in IDH1 (93%). HVEM exhibited
potential as a prognostic marker based on Cox regression and nomogrammodels. HVEM displayed intra-tumour
heterogeneity and was more highly expressed in peri-necrotic and microvascular regions. Gene ontology and
pathway analysis revealed enrichment of HVEM in multiple immune regulatory processes, such as suppression
of T cell mediated immunity in GBM. Finally, in cell lineage analysis, HVEM was found to be tightly associated
with several infiltrating immune and stromal cell types which localized to the tumour microenvironment.
Interpretation:Our data highlights the importance of HVEM in the development of GBM and as a potential molec-
ular target in combination with current immune checkpoint blockades for treatment of GBM.







Glioblastoma (GBM) is the most prevalent adult primary malignant
tumour of the central nervous system (CNS). Despite advances in ther-
apeutic methods, the life expectancy of GBM patients beyond primary
diagnosis is about 15 months [1]. Poor survival is considered in large
part to be due to the infiltrative nature [2] and microscopic spread [3]
of the cancer cells which are the basis for recurrence.
The tremendous progress in understanding the molecular mecha-
nisms underlying the development of GBM has been driving current di-
rections in GBM therapy [4,5]. Unfortunately, althoughmany molecular
targeted therapies appeared promising in preclinical models, they failedang).
en access article under the CC BY-NCto show a desirable effect in phase I, II and III clinical trials for patients
[6]. The dilemma of molecular targeted therapies mainly arises from
the clonal, evolutionary and cellular complexity of GBM [7,8]. Further-
more, the blockade of the blood-brain barrier (BBB) and rapidly devel-
oped drug resistance also attenuate the effect of drugs [9]. Given the
poor outcome of patients even under treatment with surgical and
molecular targeted therapies, immunotherapy is appealing for further
exploration as a new treatment strategy.
Immunotherapy for cancers harnesses the immune system to
destroy cancer cells. Emerging evidence demonstrates that, among the
dynamic effects of immunity, immune checkpoints are a crucial mecha-
nism in the interaction between the immune system and GBM. Defined
as a cohort of co-stimulatory and co-inhibitorymoleculesmodulating T-
cell activity, immune checkpoints orchestrate as regulatory circuits to
make the immune system self-tolerable under normal physiological cir-
cumstances [10,11]. The functions ofmany classical checkpoints in GBM-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
The dysregulation of immune checkpointmoleculeswithin tumors
has been hotly investigated in recent years as a potential therapeu-
tic target in human cancer. Herpes virus entry mediator (HVEM),
also known as tumour necrosis factor receptor (TNFR) superfamily
14 (TNFRSF14), is a novel immune checkpoint molecule which
plays essential roles in both innate and adaptive immunity. While
its function has been illuminated in diverse cancers, the clinical rel-
evance of HVEM in human gliomas remains largely unknown.
Added value of this study
We found that HVEM was elevated in aggressive gliomas, espe-
cially in GBM with wild-type isocitrate dehydrogenase (IDH). Pa-
tients with HVEMhigh expressing tumors were associated with
poorer prognosis, and HVEM expression levels showed promise
as a prognostic marker based on Cox regression and nomogram
models. HVEM protein was localized to the peri-necrotic zone
and areas of microvascular proliferation in sections from primary
human tumors. Gene ontology and pathway analysis revealed
that HVEM plays an important role in the regulation of immune re-
sponse and inflammatory activation, especially inmodulating sup-
pression of antitumor T cell immunity. HVEM was also tightly
associated with several infiltrating immune and stromal cell line-
ages in the microenvironment, as well as several classical immune
checkpoint molecules.
Implications of all the available evidence
Our study highlights the clinical and immunological importance of
HVEM in GBM. Targeting HVEM combined with current immune
checkpoint blockadesmight therefore be a novel therapeutic strat-
egy for GBM in the future.
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inhibitory checkpoint molecule expressed on T cells, which interacts
with CD80 and CD86 on antigen-presenting cells (APCs) to inhibit
co-stimulatory pathways [12]. This mechanism affects GBM antigen
presentation [13]. PD-1, expressed on T cells, mediates the interaction
between activated T cells and tumour cellswhen activated T cells return
to the CNS, and PD-1 ligand (PD-L1) expressed on GBM cells binds to
PD-1 to suppress T cell immune response [14]. Tim 3 is another check-
point molecule expressed on CD4+ and CD8+ T cells. High levels sup-
press immune response through T cell exhaustion, leading to immune
escape in cancer [15]. Immune checkpoints are often exploited by
GBM cells to escape antitumour immunity. Thus, inhibitory immune
checkpoints have been investigated as targets for GBM treatment. Stud-
ies are currently examining the feasibility of targeting immune check-
point inhibitors, such as humanized CTLA-4 antibody Ipilimumab and
PD-1 suppressive antibodies Nivolumab and Pembrolizumab, and
their efficacies are under different phase clinical trials (from I to III)
for GBM [16].
Herpes Virus Entry Mediator (HVEM), also known as tumour necro-
sis factor receptor (TNFR) superfamily 14 (TNFRSF14), is another essen-
tial immune checkpoint molecule critical in immune surveillance for
cancer [17]. HVEM is expressed on T cells, and it mainly interacts with
B and T lymphocyte attenuator (BTLA), CD160, glycoprotein D (gD),
lymphotoxin-like, inducible expression competes with Herpes Simplex
Virus glycoprotein D for HVEM, a receptor expressed by T lymphocytes
(LIGHT/TNFSF14) and lymphotoxin α (LTα3). HVEM appears to be a“molecular switch” as it exerts a co-stimulatory effect on T cells when
it binds to LIGHT or LTα but a co-inhibitory effect when it binds to
BTLA or CD160 [18,19].
HVEM has been implicated in widespread development of human
cancers.HVEM is a candidate tumour suppressor as one of themost fre-
quently mutated genes in germinal center lymphomas [20]. It is highly
expressed and negatively correlated with PD-1 expression in non-
small cell lung cancer [17] and in hepatocellular carcinoma where
only limited expression has been observed in normal liver tissue. High
HVEM expression has also been correlated with poorer recurrence-free
survival (RFS) and overall survival (OS) in hepatocellular carcinoma
[21].
Here,we investigated a potential role for HVEM inpromoting the de-
velopment of human gliomas using analysis of publicly available data-
bases. Our results demonstrated that HVEM is highly expressed in
GBM and predicted to contribute to suppressed T cell immunity,
which might be an underlying tumour promoting activity. Our study
supports HVEM as a potential prognostic marker or molecular target
in the clinical management of GBM.
2. Materials and methods
2.1. Ethics statement
The research strategywas approved by the Research Ethics Commit-
tee of Shandong University and the Ethics Committee of Qilu Hospital
(Shandong, China). All experiments were performed in accordance
with the relevant guidelines and regulations, andwritten informed con-
sent was obtained from all patients.
2.2. Clinical specimens
Archived paraffin embedded glioma tissues (WHO grades II-IV)
were collected from patients (n = 34) who underwent surgery in the
Department of Neurosurgery, Qilu Hospital of Shandong University.
Normal brain tissue samples (n = 6) were taken from trauma patients
who underwent partial resection of normal brain as decompression
treatment for severe head injuries.
2.3. Immunohistochemistry
Sections (4 μm) were obtained from formalin-fixed, paraffin-
embedded tissues of different grades of human gliomas (WHO
grades II-IV). Sections were boiled in sodium citrate buffer
(pH 6.0) for antigen retrieval, and endogenous HRP activity was
blocked with 3% H2O2. Slides were blocked with 10% normal goat
serum and incubated with primary antibody (rabbit polyclonal
anti-HVEM antibody, 1:50; Proteintech; Wuhan, China) at 4 °C over-
night. Signal was visualized using standard protocols with horse
radish peroxidase conjugated secondary antibody and 3, 3′-diamino-
benzidine (DAB) as the substrate. For negative controls, sections
were incubated with normal mouse serum rather than primary
antibody. Slides were counterstained with hematoxylin, and repre-
sentative images were obtained using an Olympus inverted
microscope.
2.4. Biological function and gene set enrichment analysis
Correlation analysis ofHVEMwas performed in gene expression pro-
files available in the TCGA and CGGA datasets with Matlab software
(https://cn.mathworks.com) and R language (https://www.r-project.
org/). To identify biological processes and the KEGG signaling pathways
associated with HVEM expression in gliomas, genes correlated with
HVEM (P b .01) were analyzed using the DAVID web tool (http://
david.abcc.ncifcrf.gov/home.jsp). Association between HVEM expres-
sion and hallmark gene sets from the Molecular Signatures Database
Fig. 1.HVEMexpression is elevated in aggressive gliomas. a.Analysis ofHVEMmRNA levels (log2) inWHOgrade II-IV gliomas fromTCGA (n=669), CGGA (n=325), and Rembrandt (n=
510) datasets. b. Receiver operating characteristic (ROC) curve to assess sensitivity and specificity ofHVEM expression as a diagnostic biomarker in gliomas. c.HVEMmRNA levels (log2) in
gliomas fromTCGAandCGGAdatasets based on the2016WHOclassification.d.Representative imagesof IHC staining forHVEM innormal brain anddifferent pathological grades of gliomas
(n=40). e.Quantification of HVEM IHC staining in normal brain (n=6) and different pathological grades of gliomas (n=34). f. Representative images of HVEM IHC staining in GBMand
adjacent brain tissues in a specific case from our cohort. Data are shown as themean ± the standard error of themean (SEM) for each group. *P b .05, **P b .01, ***P b .001.
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software (http://software.broadinstitute.org/). Somatic mutations and
somatic copy number alternations (CNAs) were downloaded from
the TCGA database. Copy number alternations associated with HVEM
expression were analyzed using GISTIC 2.0 (https://gatkforums.
broadinstitute.org).
2.5. Statistical analysis
Kaplan-Meier survival curves were generated and compared using
the log-rank test. A two-tailed χ2 test was used to determine the associ-
ation between HVEM expression and pathological characteristics. The
Pearson correlation was applied to evaluate the linear relationship be-
tween gene expression levels. The Kolmogorov–Smirnov test was used
to assess the normal distribution of data. The one-way ANOVA test or
t-test was used for all other data comparisons using GraphPad Prism
7.0 (https://www.graphpad.com/; La Jolla, CA, USA). Data for each treat-
ment group were represented as the mean ± SEM and compared with
other groups for significance by one-way ANOVA followed by
Bonferroni's post hoc test (multiple comparison tests). All tests were
two-sided, and P-values b.05 were considered to be statistically
significant.
3. Results
3.1. HVEM expression is elevated in aggressive gliomas
The mRNA expression levels of HVEM in different WHO grade glio-
mas was evaluated using expression data from publicly available data-
bases containing genomic data from over 1500 gliomas samples:
TCGA, n = 669; CGGA, n = 325; and Rembrandt, n = 510. HVEM wasFig. 2. Inter-tumour and intra-tumour heterogeneous expression characteristics of HVEM in
scheme, including CpG island methylator phenotype (G-CIMP) proneural, non–G-CIMP p
Rembrandt datasets. ROC curve indicating sensitivity and specificity of HVEM expression as a d
and PN signatures in HVEM high vs low samples in the TCGA GBM dataset. Normalized enrich
different radiographical regions of GBM and normal brain from the Gill dataset. e. Intra-tu
analysed are the following: LE (Leading Edge), IT (Infiltrating Tumour), CT (Cellular Tum
(Microvascular Proliferation), and HBV (Hyperplastic Blood Vessels).observed to be significantly up-regulated in GBM compared to low
grade glioma (LGG) samples (P b .001, respectively; Fig. 1a). The expres-
sion ofHVEMwas also higher inWHO grade III thanWHO grade II cases
in the TCGA and CGGA cohorts (P b .001, respectively; Fig. 1a). Receiver
operating characteristic (ROC) curve analysis further indicated that the
expression of HVEM discriminated gliomas from normal brain tissue
(the area under the curve (AUC) value = 0.7797; P b .001; Fig. 1b).
Thus, HVEM might be a potential diagnostic marker in gliomas.
We also evaluated HVEM levels based on the 2016 WHO classifica-
tion of CNS tumours. HVEM was downregulated in low grade
oligodendroglioma (LGG-Oligo; IDHmut, 1p/19q codeletion), low
grade astrocytoma (LGG-Astro; IDHmut, 1p/19q non-codeletion) but
upregulated in the LGG-IDHwt group in both TCGA and CGGA datasets
(Fig. 1c). Similarly, the GBM-IDHwt subtype, which is associated with
poorer clinical outcome, was associated with higher HVEM levels
(Fig. 1c).
To confirm that HVEM expression was also up-regulated at the pro-
tein level, we performed IHC staining for HVEM on an independent co-
hort of primary glioma (n = 34) and normal brain tissue (n = 6)
samples from our institution. HVEM was located in the cytoplasm and
membrane in tumours, with lower expression in normal brain tissue
(1/6; 16.7%) compared to LGG (5/12; 41.7%) and GBM (16/22; 72.7%).
Expression also increased with increasing tumour grade (Fig. 1d and
e). IHC staining in GBM case #040 showed that HVEM was positively
expressed in GBM but lower in adjacent normal brain tissue (Fig. 1f).
To determinewhether HVEMwas expressed on immune infiltrates, im-
munofluorescence staining was performed with antibodies against
HVEM and CD45, a marker for microglia/macrophages. We found no
obvious co-localization of HVEM and CD45-positive cells in tumour
sections (Fig. S1), indicating that HVEM was mainly expressed on
tumour cells in GBM. Taken together, the expression of HVEM wasgliomas. HVEM mRNA expression (log2) using VERHAAK_2010 molecular classification
roneural, neural, classical, and mesenchymal subtypes, from the a. TCGA and and b.
iagnostic biomarker for the MES molecular subtype. c. GSEA enrichment analysis of MES
ment score (NES) and FDR are shown for each plot. d. HVEM mRNA expression (log2) in
mour analysis of HVEM expression using IVY GBM RNA-seq data. Anatomic structures
our), PAN (Pseudopalisading Cells Around Necrosis), PNZ (Perinecrotic Zone), MVP
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gliomas based on large-scale analysis in silico analysis and in an inde-
pendent set of primary glioma specimens at the protein level.
3.2. Inter-tumour and intra-tumour heterogeneous characteristics of HVEM
in gliomas
Human gliomas have beenmolecularly categorized into distinct sub-
classes: classical (CL), mesenchymal (MES), proneural (PN), and neural
(NE). CL and MES subtypes are associated with more aggressive behav-
ior relative to PN orNE subtypes [22].We subsequently investigated the
inter-tumour heterogeneity of HVEM among different molecular sub-
types based on the VERHAAK_2010 classification scheme [23]. In the
TCGA dataset, increased HVEM expression was associated with theFig. 3.HVEM expression is associatedwith poor survival in glioma patients. Kaplan-Meier analys
and LGG and GBM patients in a. TCGA and and b. CGGA datasets. The median value of HVEM
c. Nomogram for predicting the proportion of glioma patients with OS. d. Plots depict the cali
performance is shown by the plot, relative to the 45-degree line, which represents perfect preMES molecular subtype compared to the NE, PN CpG island methylator
phenotype (G-CIMP) or non-G-CIMP molecular subtypes (P b .001;
Fig. 2a). The ROC curve further indicated that HVEMmight be effective
as an MES subtype predictor among gliomas (AUC value = 0.8984; P b
.001; Fig. 2a). Similar results were observed in the Rembrandt cohort
(AUC value = 0.8409; P b .001; Fig. 2b). Gene Set Enrichment Analysis
(GSEA) in TCGA GBM patients further confirmed this observation
(Fig. 2c).
The intra-tumour distribution of HVEM in GBM tissues was evalu-
ated. Radiographically, GBM tissues contained within the T1 contrast-
enhancing (CE) regions have different compositions relative to the
non-enhancing (NE; abnormal T2/FLAIR signal) GBM margins, which
represent oedematous tissues with infiltrating tumour cells. Analysis
of RNA sequencing data from 93 samples [24] revealed that HVEMwasis of overall survival (OS) based on high vs low expression ofHVEM in pan-glioma analysis,
expression was used as the cut-off value. P-values were obtained from the log-rank test.
bration of each model in terms of agreement between predicted and observed OS. Model
diction.
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areas (P b .001, respectively; Fig. 2d). Furthermore, based on the Ivy
Glioblastoma Atlas Project data, HVEM was found to be abundant in
peri-necrotic zones, microvascular proliferation and hyperplastic
blood vessels compared to other pathological areas (P b .001, respec-
tively; Fig. 2e).
3.3. HVEM expression is associated with poor survival in glioma patients
We next assessed the prognostic value of HVEM expression in
human gliomas using Kaplan-Meier analysis. Kaplan-Meier survival
curves were generated based on median values of HVEM expression in
gliomas. In pan-glioma analysis of both TCGA and CGGA datasets,
HVEMhigh patients exhibited significantly shorter overall survival (OS)
than HVEMlow patients (P b .001, respectively; Fig. 3a). Unfavorable OS
was also associatedwith higherHVEM expression in analysis performed
on patient data on the basis of different histological subtypes alone
(Fig. 3a and b). In addition, higher HVEM expression was associated
with poorer progression-free survival (PFS) among glioma patients
overall as well as LGG-Astro and GBM patients (Fig. S2a). HVEM status
remained informative among IDHwt GBM samples (P = .0382), but
was not prognostic for IDHmut GBM samples (Fig. S2b).Fig. 4.HVEMhigh or low expression is associatedwith distinct genomic alterations. a.Overall copy n
red (amplification). b. Frequency of specific changes based onHVEMlow and HVEMhigh groups. T
c. Spectrum of somatic mutations in gliomas from HVEMlow and HVEMhigh groups. d. KEGG pat
functions highly associated with HVEMhigh expressing tumours.Furthermore, we investigated whether HVEM could serve as a
marker for the prediction of patient response to radiation and che-
motherapy. HVEMlow GBM patients receiving radiotherapy exhibited
longer OS than HVEMhigh patients (P = .0135; Fig. S2c). However,
HVEMlow GBM patients displayed only a trend towards better prog-
nosis compared to the HVEMhigh group (Fig. S2c). HVEM expression
was subsequently validated as an independent prognostic marker
after adjusting for several risk factors including age, IDH status
and radiotherapy in univariate and multivariate Cox regression anal-
ysis in both LGG (HR = 2.621, 95% CI = 1.329 to 5.169, P = .005;
Table S1) and GBM (HR = 1.795, 95% CI = 1.086 to 2.967, P =
.023; Table S1) in the CGGA dataset. The prognostic value was
only significant in univariate Cox regression analysis in the TCGA
dataset (Table S1).
To better predict patient prognosis in the clinic, HVEM expression
along with clinicopathological risk factors were integrated to develop
a prognostic nomogram model (Fig. 3c). Nomograms are a graphical
representation of predictive statistical models, which generate the
probability of a clinical event, such as response to therapy, and have
been widely used for cancer patients. Calibration plots showed that
the nomograms did well in predicting patient survival according to an
ideal model (Fig. 3d).umber variation (CNV) profile according to high vs lowHVEM expression. Blue (deletion);
he Y-axis represents the frequency of chromosomal deletion (blue) or amplification (red).
hway analysis for mutations based on HVEM expression levels. Deeper brown represents
165M.-Z. Han et al. / EBioMedicine 43 (2019) 159–1703.4. HVEM expression levels are associated with distinct genomic
alterations
To determine whether HVEM expression levels were associated
with specific genomic characteristics in gliomas, we performed copy
number variation (CNV) and somatic mutation analysis using the
TCGA dataset. A distinct overall CNV profile emerged from the com-
parison of the HVEMlow (n = 162) vs the HVEMhigh (n = 163) cluster
(Fig. 4a and b). Amplification of chr7 and deletion of chr10, which
are both common genomic events in GBM, frequently occurred in
the HVEMhigh cluster (Fig. 4a). Deletion of 1p and 19q, a genomic
hallmark of oligodendroglioma, however, more frequently appeared
associated with the HVEMlow cluster (Fig. 4b). Using GSITIC analysis,
we identified 33 and 38 genomic events to be enriched in either
the HVEMhigh or HVEMlow group, respectively (Fig. 4b and Table S2).
In HVEMhigh samples, frequently amplified genomic regions included
oncogenic driver genes such as EGFR (7p11.2), PDGFRA (4q12) and
CDK4 (12q14.1), while deleted regions contained tumour suppressor
genes including CDKN2A/CDKN2B (9p21.3) and PTEN (10q23.3). Anal-
ysis of somatic mutation profiles based on HVEM expression levels
revealed a high frequency of mutations in EGFR (31%), PTEN (28%),Fig. 5. HVEM-related biological functions in gliomas. Biological processes assessed using the se
databases. c. Network representation of pathway terms enriched in HVEM-positively associat
results were plotted using Cytoscape.TTN (25%) and NF1 (15%) in the HVEMhigh group (n = 163), while
IDH1 (93%), ATRX (33%), CIC (28%) were more frequently mutated
in the HVEMlow group (n = 162; Fig. 4c). Finally, genomic mutations
associated with HVEM expression levels were linked to functionally
distinct biological pathways. HVEMlow expressing tumours, for exam-
ple, harbored mutations associated with 2-oxocarboxylic acid metab-
olism, the TCA cycle, and glutathione metabolism. EGFR tyrosine
kinase inhibitor resistance, the ErbB signaling pathway, and the Ras
signaling pathway were the significant differential pathways which
had higher mutation rates among HVEMHigh expressing tumours
(Fig. 4d and Table S3).
Since the HVEM gene is located on 1p36, a chromosomal band de-
leted in 20–40% of all types of gliomas [25–27],we also examined the re-
lationship between HVEM copy number (CN) and HVEM expression
levels. In both LGGs and GBMs, tumours with HVEM CN loss expressed
significantly lower levels of HVEM mRNA (P b .001, respectively;
Fig. S3a and S3b). Moreover, in an independent dataset, glioma samples
with 1p deletion expressed significantly lower levels of HVEM than 1p
intact tumours (P b .01; Fig. S3c). Thus, these data demonstrated that
HVEM expression could be regulated by gross chromosomal changes
in human gliomas.t of HVEM-associated genes in a. TCGA and b. CGGA datasets. Results are based on the GO
ed gene signatures. Categorical enrichment was calculated using DAVID, and enrichment
166 M.-Z. Han et al. / EBioMedicine 43 (2019) 159–1703.5. Genes positively associated with HVEMare enriched in immune related
processes
We investigated the potential function of HVEM in the development
of human glioma by using GO analysis on genes positively associated
with HVEM expression. GO results with the genes from either datasetFig. 6.HVEM is associatedwith T cell immunity and inflammatory activities in gliomas. a.GSEA a
normalized enrichment score (NES). Blue, positive association; red, negative association.b.GSEA
dataset. NES and FDR are shown for each plot. Heatmaps illustratingHVEM related inflammatory
inflammatory metagenes in c. TCGA and d. CGGA datasets. Expression values are z-transforme
scale bar.(TCGA, n = 756 genes; CGGA, n = 733 genes; Table S4) revealed that
they were enriched in a wide variety of immune-related functions, in-
cluding innate immune response, inflammatory response, leukocyte
migration, NF-κB signaling regulation, TNF mediated signaling, and
type I interferon (Fig. 5a and b). The signaling network that resulted
from KEGG pathway analysis further established the associationnalysis links HVEMhigh vs low gene signatures to T cell immunity. TheX-axis indicates the
plots for enrichment of T cell immunity inHVEMhigh vs HVEMlow samples in the TCGAGBM
activities in gliomas. Corrgrams illustrate Pearson r values for analysis betweenHVEMand
d and are colored red for high expression and blue for low expression, as indicated in the
167M.-Z. Han et al. / EBioMedicine 43 (2019) 159–170between HVEM and immune-related pathways, such as TNF signaling
and apoptosis (Fig. 5c). These data suggested that HVEMmight play es-
sential roles in immune related processes in gliomas.
3.6. HVEM is associated with T cell immunity in gliomas
HVEM on tumour cells has been reported to suppress cytokine pro-
duction and proliferation of CD8+T cells through BTLA [28]. In hemato-
poietic cells, HVEM is found to be involved in both T-cell activation and
inhibition processes depending on the ligands [29,30]. We thus investi-
gated whether HVEM might have a role in T cell immunity in gliomas
using GSEA analysis. We found that HVEM was negatively associated
with regulation of T cell mediated immunity, regulation of T cell recep-
tor signaling, regulation of T cell mediated cytotoxicity, and T cell prolif-
eration (Fig. 6a and b). In contrast,HVEMwas positively associatedwithFig. 7. HVEM is associated with tumour purity and immune and stromal cell populations in the
and tumour purity in TCGA a. LGG and b.GBM samples. Heatmaps illustrating the relationship b
GBM data. Expression values are z-transformed and are colored red for high expression and blregulation of T helper cell differentiation, regulation of T helper 1 type
immune response, antigen processing and presentation through MHC
class I molecules, and regulation of alpha beta T cell activation. Thus,
HVEM may contribute to the suppression of T cell associated anti-
tumour immunity in the glioma microenvironment.
3.7. HVEM is involved in inflammatory activities in gliomas
Based on our in silico analysis which implicated HVEM in the inflam-
matory response in gliomas, we examined the association of the mole-
cule with various inflammatory activity signatures [31]. HVEM
expression was found to be positively associated with HCK, interferon,
LCK, MHC-I, MHC-II, and STAT1 metagenes, but negatively associated
with the IgG metagene in pan-glioma analysis (Fig. 6c and d) and
GBM alone (Fig. S4a and S4b). These findings indicated that HVEMtumour microenvironment. Correlation analysis of HVEMhigh or HVEMlow expression levels
etweenHVEM and 64 immune and stromal cell populations based on c. TCGA and d. CGGA
ue for low expression, as indicated in the scale bar.
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duction, and antigen presenting cells, but not interaction with B lym-
phocytes during immunosuppression and glioma progression.
3.8. HVEM is associated with increased immune and stromal cell popula-
tions in the tumour microenvironment
To further examine the significance of increased HVEM in gliomas,
we performed analysis to identify the cell types or activities in the tu-
mour microenvironment that might be influenced by the molecule. In
this analysis, HVEMwas found to be negatively correlated with glioma
cell purity for both LGG (Fig. 7a) and GBM (Fig. 7b) samples in indepen-
dent analyses. Moreover, a tight association was found between HVEM
levels and the immune or microenvironment score in GBM samples
from both TCGA and CGGA datasets (Fig. 7c and d).
To comprehensively evaluate its putative role in tumour-immune
cell interactions, we investigated the relationship between HVEM and
64 immune and stromal cell populations using cell type enrichment
analysis [32].HVEMwas tightly associatedwithmultiple infiltrating im-
mune cell types, including monocytes, macrophages, CD8+ T effector
memory cells (TEM), CD4+ TEM, neutrophils, DCs and NK cells; how-
ever, HVEM was negatively associated with pro B-cells, plasma cells
and CD8+ naive T cells (heatmaps in Fig. 7c and d). In addition, specific
stromal cell types, such as epithelial cells, astrocytes and fibroblasts,
were also enriched in HVEMhigh GBMs. These findings were further val-
idated based on a 9-immune cell lineage analysis, confirming the en-
richment of multiple immune cell lineages [33] in HVEMhigh glioma
samples (Fig. S5a-S5d). All together, our data suggested that HVEMhigh
glioma samples tend to recruit infiltrating immune and stromal cells
into the tumour microenvironment.Fig. 8. HVEM is associated with other immune checkpoint molecules in gliomas. Correlation o
samples (lower row) in (a, b) TCGA, (c, d) CGGA, and (e, f) Rembrandt datasets.3.9. HVEM is associated with other immune checkpoint molecules in
gliomas
Given the vital functions of immune checkpoint molecules in the
regulation of immune processes, we performed correlation analysis to
assess the relationship betweenHVEM and severalwell-known immune
checkpoint genes in glioma samples. HVEMwas highly correlated with
TIM-3, PD-1, PD-L1, CTLA-4, LAG3 and VISTA in pan-glioma analysis and
GBM samples alone in all 3 datasets (Fig. 8a - 8f). We also observed a
synergistic association between HVEM and its receptors (BTLA and
CD160) or ligands (LIGHT and LTA). A strong positive association
emerged between HVEM and LIGHT or BTLA in pan-glioma analysis
and GBM samples alone. No significant relationship was observed be-
tween HVEM and CD160 or LTA (Fig. S6a–S6f). These results highlight
HVEM/LIGHT and HVEM/BTLA potentially as major signaling pathways
involved in immunosuppression in the glioma microenvironment.
Based on these findings, we used univariate Cox regression analysis
to explore the prognostic value ofHVEM, LIGHT or BTLA in GBMpatients.
A risk score formula for survival prediction was constructed based on a
linear combination of the mRNA expression levels of the three genes
and weighted by the regression coeffcient from the univariate Cox re-
gression analyses (β) [34]: risk value = (0.304 × HVEM expression) +
(0.331× LIGHT expression)+ (0.049 × BTLA expression). Using theme-
dian risk score as the cutoff value, the patientswere successfully divided
into high- and low-risk groups for each grade. In Kaplan-Meier survival
analysis of the LGG andGBM cohorts from CGGA and TCGA datasets, pa-
tients with high-risk scores exhibited shorter OS than those with low-
risk scores (Fig. S7a and S7b). Taken together, the HVEM risk score
may serve as a useful gene-signature marker for selecting high-risk pa-
tients to receive more personalized treatments in the future.f HVEM and immune checkpoint molecules in pan-glioma analysis (upper row) and GBM
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Based on a comprehensive, large-scale bioinformatic analysis, we
characterized the landscape of HVEM among gliomas. HVEMmRNA ex-
pression levels were found to be highly upregulated in GBM, especially
in the GBM-IDHwt subtype based on the 2016 WHO classification.
HVEMhigh or low expression served as a sensitive diagnostic marker with
higher expression in the MES molecular subtype of gliomas. HVEM
was localized to peri-necrotic regions, microvascular proliferation and
hyperplastic blood vessels. Moreover, a nomogram predictive model
was established based on HVEM and several risk factors, which appears
promising as a tool for clinical management of patients.
GBM attracts a variety of immune cell types from both the innate
and adaptive immune systems, thus defying assumptions about im-
mune privilege with regard to the human brain. The discovery of a
unique system of lymphatic vessels in the CNS in 2015 provides a direct
channel for T cells to interact with antigens in the CNS [35]. In addition,
it has been demonstrated that APCs can present antigens in the CNS to T
cells, and the antigen-specific T cells can respond to CNS antigens [13].
Furthermore, tumour development interferes with the integrity of the
BBB, which can enable a direct immune response to GBM [13]. A mech-
anism regulating immune response to GBM is immune checkpoints. Im-
mune checkpoint molecules are primarily utilized to regulate the
activity of T lymphocytes, and they can stimulate or inhibit function. In-
hibitory checkpoint molecules are often exploited by GBM, as expres-
sion levels are increased in the disease as a mechanism of escape from
immune surveillance [13]. Checkpoint molecules PD-1 and CTLA-4, for
example, play a critical role in debilitating the immune response against
GBM. PD-1 expressed on T cells receives an inhibitory signal from PD-L1
on APCs or GBM cells which leads to reduced T cell activity, cytotoxic ef-
fects of T cells and cytokine production [36,37]. CTLA-4mainly functions
betweenAPCs and T cells to inhibit other stimulatory pathways of T cells
[12].
HVEM, also known as CD270, is an immune checkpoint receptor be-
longing to the tumour necrosis factor receptor (TNFR) superfamily [38].
The HVEM gene has been found to be mutated or over-expressed in di-
verse cancers. Higher expression ofHVEM is also associatedwith poorer
prognosis in cancers including germinal center lymphomas [20], non-
small cell lung cancer [17], hepatocellular carcinoma [21], breast cancer
[39], colorectal cancer [40], ovarian cancer [41] and gastric cancer [42].
These results indicate that HVEM widely participates in oncogenic
processes.
HVEM is unique among TNFRSF proteins, in part due to that fact it
transduces both pro-inflammatory and inhibitory signals [43]. As a ca-
nonical TNF receptor, HVEM signals through TNF receptor-associated
factors (TRAFs) to activate nuclear factor-κB (NF-κB) transcription fac-
tors, which control transcription of genes essential for cell survival and
inflammation [44–46]. Through GO and KEGG analysis, we found that
HVEM function is closely associated with inflammation and immune
signaling pathways, such as NF-κB signaling regulation and TNF medi-
ated signaling. Our results are thus consistent with the reported func-
tion of HVEM.
Previous studies have also identified a tight association between
HVEM and T cell activity; HVEM was found to be involved in both
T cell activation and inhibition depending on the ligands [18,19]. In
our study, we found HVEM to be negatively associated with T cell im-
munity as well as T helper cell activity. Furthermore, the correlation
analysis between HVEM and microenvironment components sug-
gested that HVEMhigh GBM cells tend to recruit more infiltrating im-
mune and stromal cells into the tumour microenvironment,
including monocytes, macrophages, CD8+ and CD4+ TEM, neutro-
phils, DCs and NK cells. These data support a function for HVEM as
a contributor to the suppressive anti-tumour immunity in the glioma
microenvironment. However, further studies are needed to elucidate
the interaction network between HVEM and infiltrating immune
cells.Several immune checkpoint inhibitors have exhibited preclinical
benefits, such as Ipilimumab and Tremelimumab for CTLA-4, and
Nivolumab and Pembrolizumab for PD-1. We also analyzed the interac-
tion between HVEM and immune checkpoint molecules. HVEM was
highly correlated with TIM-3, PD-1, PD-L1, CTLA-4, LAG3 and VISTA in
both pan-glioma analysis and GBM samples alone. The correlation be-
tween HVEM and somany classic immune checkpoint molecules estab-
lishes a solid basis for combined immune checkpoint blockade,
targeting HVEM or other molecules, as a novel approach for clinical
management of glioma.
Based on protein structures, immune checkpoint proteins are di-
vided into two families, the immunoglobulin (Ig) or tumour necrosis
factor receptor superfamily (TNFRSF). As a canonical TNFR checkpoint,
HVEM mainly interacts with molecules including BTLA, CD160, gD,
LIGHT and LTα3 [18]. We found a strong correlation between HVEM
and LIGHT or BTLA in gliomas. However, no significant relationship
was observed between HVEM and CD160 or LTα3. Thus, LIGHT and
BTLA may dominate HVEM-mediated immunosuppression activities in
glioma. Consistent with our findings, previous studies have reported
that HVEM transduces a pro-inflammatory signal through activation of
the NF-κB pathway after interacting with/binding to BTLA. The activa-
tion of HVEM/BTLA signaling has been observed in cancer, including
gastric cancer and hepatocellular carcinoma [21,42], which can lead to
inhibition of T cell activity in the disease. Thus, a blockade of this path-
way could possibly enhance/reactivate the anticancer effect of T cells
[47]. However, further study is needed to elucidate the function of
HVEM signaling in the development of human glioma.
Taken together, ourwork illuminates a possible role for HVEM in the
development and treatment of human gliomas. Future studies are war-
ranted for further investigation of HVEM as a new immune-therapeutic
target or prognostic marker for GBM.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.04.002.
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